Biomarkers for lysosomal storage disorders: Identification and application as exemplified by chitotriosidase in Gaucher disease

Acta Paediatrica, International Journal of Paediatrics

Volumn 97, Issue SUPPL. 457, 2008, Pages 7-14

  Aerts, Johannes M ^a   Van Breemen, Marielle J ^a   Bussink, Anton P ^a   Ghauharali, Karen ^a   Sprenger, Richard ^a   Boot, Rolf G ^a   Groener, Johanna E ^a   Hollak, Carla E ^a   Maas, Mario ^a   Smit, Suzanne ^b   Hoefsloot, Huub C ^b   Smilde, Age K ^b   Vissers, Johannes P C ^c   De Jong, Sheryas ^a   Speijer, Dave ^a   De Koster, Chris G ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c WATERS CORPORATION   (United States)

Author keywords

Biomarker; Chitotriosidase; Gaucher disease; Lysosomal storage disorder; Mass spectrometry

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; BETA N ACETYLHEXOSAMINIDASE; BIOLOGICAL MARKER; CATHEPSIN K; CHITOTRIOSIDASE; DIPEPTIDYL CARBOXYPEPTIDASE; LYSOZYME; PLASMA PROTEIN; PROTEIN;

BLOOD SAMPLING; CLINICAL ASSESSMENT; CONFERENCE PAPER; DIAGNOSTIC PROCEDURE; DISEASE COURSE; ENZYME REPLACEMENT; GAUCHER DISEASE; LIPIDOSIS; LIQUID CHROMATOGRAPHY; LYSOSOME STORAGE DISEASE; MACROPHAGE; MASS SPECTROMETRY; METABOLITE; MONITORING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TIME OF FLIGHT MASS SPECTROMETRY; TREATMENT INDICATION; TREATMENT PLANNING;

BETA-GLUCOSIDASE; BIOLOGICAL MARKERS; GAUCHER DISEASE; HEXOSAMINIDASES; HUMANS; LYSOSOMAL STORAGE DISEASES; MACROPHAGES; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 41049104711     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1111/j.1651-2227.2007.00641.x     Document Type: Conference Paper

References (64)

1. EMEA. Report on the EMEA/CHMP Biomarkers Workshop, European Medicines Agency. 2006 : http://www.emea.europa.eu/pdfs/human/biomarkers/42720905en.pdf.
2. Maas M, Hollak CE, Akkerman EM, Aerts JM, Stoker J, den Heeten GJ. Quantification of skeletal involvement in adults with type I Gaucher's disease: fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter. Am J Roentgenol 2002 179 : 961 5.
3. Gieselmann V. Lysosomal storage diseases. Biochim Biophys Acta 1995 1270 : 103 36.
4. Beutler E, Grabowski G. Gaucher disease. In : Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited diseases. New York : McGraw-Hill, 2001 : 3635 68.
5. Brady RO, Kanfer JN, Bradley RM, Shapiro D. Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease. J Clin Invest 1966 45 : 1112 15.
6. Patrick A. A deficiency of glucocerebrosidase in Gaucher's disease. Biochem J 1965 97 : 17c 18c.
7. Sidransky E. Gaucher disease: complexity in a "simple" disorder. Mol Genet Metab 2004 83 : 6 15.
8. Jonsson LM, Murray GJ, Sorrell SH, Strijland A, Aerts JF, Ginns EI, et al. Biosynthesis and maturation of glucocerebrosidase in Gaucher fibroblasts. Eur J Biochem 1987 164 : 171 9.
9. van Weely S, van den Berg M, Barranger J, Sa Miranda MC, Tager JM, Aerts J. Role of pH in determining the cell-type specific residual activity of glucocerebrosidase in type 1 Gaucher disease. J Clin Invest 1993 91 : 1167 75.
10. Aerts JM, van Weely S, Boot R, Hollak CE, Tager JM. Pathogenesis of lysosomal storage disorders as illustrated by Gaucher disease. J Inherit Metab Dis 1993 16 : 288 91.
11. Cox TM, Schofield JP. Gaucher's disease: clinical features and natural history. Baillieres Clin Haematol 1997 10 : 657 89.
12. Lachmann RH, Grant IR, Halsall D, Cox TM. Twin pairs showing discordance of phenotype in adult Gaucher's disease. Q J Med 2004 97 : 199 204.
13. van Weely S, Brandsma M, Strijland A, Tager JM, Aerts JM. Demonstration of the existence of a second, non-lysosomal glucocerebrosidase that is not deficient in Gaucher disease. Biochim Biophys Acta 1993 1181 : 55 62.
14. Boot RG, Verhoek M, Donker-Koopman W, Strijland A, van Marle J, Overkleeft HS, et al. Identification of the non-lysosomal glucosylceramidase as beta-glucosidase 2. J Biol Chem 2007 282 : 1305 12.
15. Yildiz Y, Matern H, Thompson B, Allegood JC, Warren RL, Ramirez DM, et al. Mutation of beta-glucosidase 2 causes glycolipid storage disease and impaired male fertility. J Clin Invest 2006 116 : 2985 94.
16. Boven LA, van Meurs M, Boot RG, Mehta A, Boon L, Aerts JM, et al. Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Pathol 2004 122 : 359 69.
17. van Breemen MJ, de Fost M, Voerman JS, Laman JD, Boot R, Maas M, et al. Increased plasma macrophage inflammatory protein (MIP)-1 alpha and MIP-1 beta levels in type 1 Gaucher disease. Biochim Biophys Acta 2007 1772 : 788 96.
18. Aerts JM, Hollak CE. Plasma and metabolic abnormalities in Gaucher's disease. Baillieres Clin Haematol 1997 10 : 691 709.
19. Boot RG, Verhoek M, de Fost M, Hollak CE, Maas M, Bleijlevens B, et al. Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood 2004 103 : 33 9.
20. Cox TM. Gaucher disease: understanding the molecular pathogenesis of sphingolipidoses. J Inherit Metab Dis 2001 24 (Suppl 2) : 106 21.
21. Moran MT, Schofield JP, Hayman AR, Shi GP, Young E, Cox TM. Pathologic gene expression in Gaucher disease: up-regulation of cysteine proteinases including osteoclastic cathepsin K. Blood 2000 96 : 1969 78.
22. Barton NW, Furbish FS, Murray GJ, Garfield M, Brady RO. Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci USA 1990 87 : 1913 16.
23. Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, Hrebicek M, et al. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 2000 355 : 1481 5.
24. Aerts JM, Hollak CE, Boot RG, Groener JE, Maas M. Substrate reduction therapy of glycosphingolipid storage disorders. J Inherit Metab Dis 2006 29 : 449 56.
25. Cox TM, Aerts JM, Andria G, Beck M, Belmatoug N, Bembi B, et al. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J Inherit Metab Dis 2003 26 : 513 26.
26. Bussink AP, van Eijk M, Renkema GH, Aerts JM, Boot RG. The biology of the Gaucher cell: the cradle of human chitinases. Int Rev Cytol 2006 252 : 71 128.
27. Hollak CE, van Weely S, van Oers MH, Aerts JM. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 1994 93 : 1288 92.
28. Renkema GH, Boot RG, Muijsers AO, Donker-Koopman WE, Aerts JM. Purification and characterization of human chitotriosidase, a novel member of the chitinase family of proteins. J Biol Chem 1995 270 : 2198 202.
29. Boot RG, Renkema GH, Strijland A, van Zonneveld AJ, Aerts JM. Cloning of a cDNA encoding chitotriosidase, a human chitinase produced by macrophages. J Biol Chem 1995 270 : 26252 6.
30. Aguilera B, Ghauharali-van der Vlugt K, Helmond MT, Out JM, Donker-Koopman WE, Groener JE, et al. Transglycosidase activity of chitotriosidase: improved enzymatic assay for the human macrophage chitinase. J Biol Chem 2003 278 : 40911 16.
31. Boot RG, Renkema GH, Verhoek M, Strijland A, Bliek J, de Meulemeester TM, et al. The human chitotriosidase gene. Nature of inherited enzyme deficiency. J Biol Chem 1998 273 : 25680 5.
32. Schoonhoven A, Rudensky B, Elstein D, Zimran A, Hollak CE, Groener JE, et al. Monitoring of Gaucher patients with a novel chitotriosidase assay. Clin Chim Acta 2007 381 : 136 9.
33. de Fost M, Hollak C, Groener JE, Aerts J, Maas M, Poll L, et al. Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis. Blood 2006 108 : 830 5.
34. Boot RG, Verhoek M, Langeveld M, Renkema GH, Hollak CE, Weening JJ, et al. CCL18: a urinary marker of Gaucher cell burden in Gaucher patients. J Inherit Metab Dis 2006 29 : 564 71.
35. Deegan PB, Moran MT, McFarlane I, Schofield JP, Boot RG, Aerts JM, et al. Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease. Blood Cells Mol Dis 2005 35 : 259 67.
36. Hollak C, Maas M, Aerts J. Clinically relevant therapeutic endpoints in type 1 Gaucher disease. J Inherit Metab Dis 2001 24 (Suppl 2) : 97 105.
37. Zimran A, Elstein D, Beutler E. Low-dose therapy trumps high-dose therapy again in the treatment of Gaucher disease. Blood 2006 108 : 802 3.
38. Hollak C, de Fost M, Aerts J, vom Dahl S. Low-dose versus high-dose therapy for Gaucher disease: goals and markers. Blood 2007 109 : 387 8.
39. Hollak C, Vedder AC, Linthorst G, Aerts J. Novel therapeutic targets for the treatment of Fabry disease. Expert Opin Ther Targets 2007 11 : 821 33.
40. Groener JE, Poorthuis BJ, Kuiper S, Helmond MT, Hollak CE, Aerts JM. HPLC for simultaneous quantification of total ceramide, glucosylceramide, and ceramide trihexoside concentrations in plasma. Clin Chem 2007 53 : 742 7.
41. Erikson A, Forsberg H, Nilsson M, Astrom M, Mansson JE. Ten years' experience of enzyme infusion therapy of Norrbottnian (type 3) Gaucher disease. Acta Paediatr 2006 95 : 312 7.
42. Mills K, Morris P, Lee P, Vellodi A, Waldek S, Young E, et al. Measurement of urinary CDH and CTH by tandem mass spectrometry in patients hemizygous and heterozygous for Fabry disease. J Inherit Metab Dis 2005 28 : 35 48.
43. An Y, Young SP, Kishnani PS, Millington DS, Amalfitano A, Corz D, et al. Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease. Mol Genet Metab 2005 85 : 247 54.
44. Tomatsu S, Gutierrez MA, Ishimaru T, Pena OM, Montano AM, Maeda H, et al. Heparan sulfate levels in mucopolysaccharidoses and mucolipidoses. J Inherit Metab Dis 2005 28 : 743 57.
45. Tomatsu S, Okamura K, Maeda H, Taketani T, Castrillon SV, Gutierrez MA, et al. Keratan sulphate levels in mucopolysaccharidoses and mucolipidoses. J Inherit Metab Dis 2005 28 : 187 202.
46. Randall DR, Sinclair GB, Colobong KE, Hetty E, Clarke LA. Heparin cofactor II-thrombin complex in MPS I: a biomarker of MPS disease. Mol Genet Metab 2006 88 : 235 43.
47. Bekri S, Lidove O, Jaussaud R, Knebelmann B, Barbey F. The role of ceramide trihexoside (globotriaosylceramide) in the diagnosis and follow-up of the efficacy of treatment of Fabry disease: a review of the literature. Cardiovasc Hematol Agents Med Chem 2006 4 : 289 97.
48. Young E, Mills K, Morris P, Vellodi A, Lee P, Waldek S, et al. Is globotriaosylceramide a useful biomarker in Fabry disease? Acta Paediatr 2005 94 (Suppl 447 51 4.
49. Whitfield PD, Calvin J, Hogg S, O'Driscoll E, Halsall D, Burling K, et al. Monitoring enzyme replacement therapy in Fabry disease: role of urine globotriaosylceramide. J Inherit Metab Dis 2005 28 : 21 33.
50. Anderson L. Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J Physiol 2005 563 : 23 60.
51. Moore DF, Krokhin OV, Beavis RC, Ries M, Robinson C, Goldin E, et al. Proteomics of specific treatment-related alterations in Fabry disease: a strategy to identify biological abnormalities. Proc Natl Acad Sci USA 2007 104 : 2873 8.
52. Lill J. Proteomic tools for quantitation by mass spectrometry. Mass Spectrom Rev 2003 22 : 182 94.
53. Hamdan M, Righetti PG. Modern strategies for protein quantification in proteome analysis: advantages and limitations. Mass Spectrom Rev 2002 21 : 287 302.
54. Ong SE, Mann M. Mass spectrometry-based proteomics turns quantitative. Nat Chem Biol 2005 1 : 252 62.
55. Silva JC, Gorenstein MV, Li GZ, Vissers JP, Geromanos SJ. Absolute quantification of proteins by LCMSE: a virtue of parallel MS acquisition. Mol Cell Proteomics 2006 5 : 144 56.
56. Vissers JP, Langridge JI, Aerts JM. Analysis and quantification of diagnostic serum markers and protein signatures for Gaucher disease. Mol Cell Proteomics 2007 6 : 755 66.
57. Hollak CE, Levi M, Berends F, Aerts JM, van Oers MH. Coagulation abnormalities in type 1 Gaucher disease are due to low-grade activation and can be partly restored by enzyme supplementation therapy. Br J Haematol 1997 96 : 470 6.
58. van Breemen MJ, Bleijlevens B, de Koster CG, Aerts J. Limitations in quantitation of the biomarker CCL18 in Gaucher disease blood samples by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Biochem Biophys Acta 2006 1764 : 1626 32.
59. Smit S, van Breemen MJ, Hoefsloot HC, Smilde AK, Aerts JM, de Koster CG. Assessing the statistical validity of proteomics based biomarkers. Anal Chim Acta 2007 592 : 210 17.
60. Aerts JM, Hollak CE, van Breemen M, Maas M, Groener JE, Boot RG. Identification and use of biomarkers in Gaucher disease and other lysosomal storage diseases. Acta Paediatr 2005 94 (Suppl 447 43 6.
61. Winchester B. Are there useful biochemical markers of disease activity in lysosomal storage diseases? J Inherit Metab Dis 2001 24 (Suppl 2 52 6.
62. Guo Y, He W, Boer AM, Wevers RA, de Bruijn AM, Groener JE, et al. Elevated plasma chitotriosidase activity in various lysosomal storage disorders. J Inherit Metab Dis 1995 18 : 717 22.
63. Brinkman J, Wijburg FA, Hollak CE, Groener JE, Verhoek M, Scheij S, et al. Plasma chitotriosidase and CCL18: early biochemical surrogate markers in type B Niemann-Pick disease. J Inherit Metab Dis 2005 28 : 13 20.
64. Vedder AC, Cox-Brinkman J, Hollak CE, Linthorst GE, Groener JE, Helmond MT, et al. Plasma chitotriosidase in male Fabry patients: a marker for monitoring lipid-laden macrophages and their correction by enzyme replacement therapy. Mol Genet Metab 2006 89 : 239 44.